Free Trial

Enliven Therapeutics (ELVN) Competitors

Enliven Therapeutics logo
$22.66 -0.68 (-2.91%)
Closing price 04:00 PM Eastern
Extended Trading
$22.68 +0.02 (+0.09%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ELVN vs. ZLAB, PTCT, RARE, AAPG, MRUS, ACLX, SWTX, RNA, ACAD, and SRRK

Should you be buying Enliven Therapeutics stock or one of its competitors? The main competitors of Enliven Therapeutics include Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), ACADIA Pharmaceuticals (ACAD), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

Enliven Therapeutics vs. Its Competitors

Zai Lab (NASDAQ:ZLAB) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Enliven Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -60.26%. Enliven Therapeutics' return on equity of -31.84% beat Zai Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Zai Lab-60.26% -33.35% -23.28%
Enliven Therapeutics N/A -31.84%-30.09%

Zai Lab presently has a consensus price target of $54.28, suggesting a potential upside of 61.68%. Enliven Therapeutics has a consensus price target of $41.20, suggesting a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Zai Lab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zai Lab has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

In the previous week, Enliven Therapeutics had 3 more articles in the media than Zai Lab. MarketBeat recorded 7 mentions for Enliven Therapeutics and 4 mentions for Zai Lab. Zai Lab's average media sentiment score of 1.19 beat Enliven Therapeutics' score of 0.71 indicating that Zai Lab is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zai Lab
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

41.7% of Zai Lab shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.0% of Zai Lab shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enliven Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zai Lab$398.99M9.35-$257.10M-$2.49-13.48
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80

Summary

Enliven Therapeutics beats Zai Lab on 10 of the 14 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELVN vs. The Competition

MetricEnliven TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.15B$2.46B$5.54B$9.41B
Dividend YieldN/A1.80%3.75%4.03%
P/E RatioN/A4.4521.0120.09
Price / SalesN/A709.89433.8199.01
Price / CashN/A164.7736.1658.27
Price / Book3.575.008.125.65
Net Income-$89.02M$30.99M$3.25B$257.91M
7 Day Performance0.94%1.69%0.97%2.09%
1 Month Performance5.05%9.20%7.36%11.13%
1 Year Performance0.27%-1.25%31.31%18.40%

Enliven Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELVN
Enliven Therapeutics
2.8636 of 5 stars
$22.66
-2.9%
$41.20
+81.8%
-1.8%$1.15BN/A0.0050News Coverage
ZLAB
Zai Lab
3.3179 of 5 stars
$35.48
-2.5%
$54.28
+53.0%
+92.2%$4.04B$398.99M-14.251,869
PTCT
PTC Therapeutics
4.4456 of 5 stars
$47.98
-2.2%
$65.00
+35.5%
+41.9%$3.89B$806.78M7.371,410News Coverage
Insider Trade
Analyst Revision
RARE
Ultragenyx Pharmaceutical
4.3814 of 5 stars
$39.61
-0.8%
$87.00
+119.6%
-37.5%$3.77B$560.23M-6.741,294Trending News
Analyst Revision
Gap Down
AAPG
Ascentage Pharma Group International
N/A$42.04
-1.9%
N/AN/A$3.73B$134.35M0.00600Lockup Expiration
MRUS
Merus
1.9328 of 5 stars
$52.58
-2.3%
$84.64
+61.0%
+8.6%$3.73B$36.13M-12.8937News Coverage
Insider Trade
ACLX
Arcellx
2.5337 of 5 stars
$65.55
-2.4%
$111.23
+69.7%
+8.3%$3.70B$107.94M-21.9280Positive News
SWTX
SpringWorks Therapeutics
1.3584 of 5 stars
$46.99
flat
$52.57
+11.9%
N/A$3.54B$191.59M-13.78230News Coverage
RNA
Avidity Biosciences
2.1866 of 5 stars
$28.80
-1.3%
$65.59
+127.7%
-24.6%$3.52B$10.90M-9.60190
ACAD
ACADIA Pharmaceuticals
3.9879 of 5 stars
$20.88
-0.3%
$27.88
+33.5%
+22.9%$3.51B$957.80M15.24510
SRRK
Scholar Rock
3.1299 of 5 stars
$35.48
-1.4%
$42.67
+20.3%
+378.9%$3.42B$33.19M-14.02140Analyst Forecast
Insider Trade

Related Companies and Tools


This page (NASDAQ:ELVN) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners